The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor. Since high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) can cure a proportion of such patients, provided that a substantial tumor shrinkage is achieved, the development of more effective and less toxic salvage regimens remains a major challenge. We evaluated the clinical activity, toxicity and mobilizing capacity of a new salvage regimen, which combines gemcitabine and oxaliplatin with ifosfamide and rituximab (R-GIFOX) in patients with relapsed and refractory CD20 + NHL.
introduction
Despite the significant improvements achieved with CHOP and CHOP-like induction regimens, 40%-50% of patients with aggressive non-Hodgkin's lymphoma (NHL) either fail to achieve a complete response (CR) or relapse after frontline therapy [1] . Unfortunately, the prognosis of patients with relapsed or progressive disease is usually poor. Highdose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) may cure a proportion of these patients, provided that a CR or at least a good quality partial remission (PR) can be achieved by appropriate salvage chemotherapy [2] .
Effective salvage therapies for NHL patients should, therefore, have significant cytoreductive activity, little extra-hematologic toxicity and sufficient mobilizing capacity (with minimal damage to endogenous stem cells) to allow the collection of adequate numbers of peripheral stem cells. An acceptable toxicity profile may also allow regimens to be used for an adequate number of courses in pretreated patients who cannot undergo high-dose procedures. Finally, salvage regimens should ideally be able to treat occult lymphoma in patients at high risk of central nervous system (CNS) involvement [3] .
We have designed a new short-course (bi-weekly), doseintensive, cytoreductive/mobilizing salvage regime which symposium article *Correspondence to: Dr A. Pinto, Hematology-Oncology Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola, I-80131, Naples, Italy. Tel: +39-081-5903-382; Fax: +39-081-5903-833; E-mail: apinto.int.napoli@tin.it ª 2006 European Society for Medical Oncology combines gemcitabine, oxaliplatin, ifosfamide and rituximab (R-GIFOX) in patients with relapsed and refractory CD20 + NHL of aggressive histology. The strategy underlying R-GIFOX is to combine three non-CHOP cross-resistant agents to provide a short-term, intensive salvage regimen aimed at maximal cytoreduction and optimal mobilization. To this end an ifosfamide dose was chosen that is high enough for adequate mobilization and cytoreduction. Gemcitabine and oxaliplatin are given at close to optimal cytotoxic dosage. Gemcitabine, a highly active drug in both NHL and Hodgkin's disease (HD) [4] , can effectively substitute for the cytarabine commonly employed in standard salvage regimens (i.e. DHAP). Gemcitabine synergizes with both rituximab and ifosfamide, a bifunctional alkylator that is one of the most active non-cross resistant drugs in second-line therapy of lymphoma. Ifosfamide displays strong cytoreductive and mobilizing activity in addition to optimal CNS penetration, facilitating clearance of occult disease [5, 6] . Cisplatin is also considered a key agent in second-line treatment of NHL [2] and HD [7] . Unfortunately, renal and neurological toxicities, both acute and delayed, preclude many patients from adequate treatment and reduce the impact of cisplatin therapy on survival. Replacement of cisplatin by its better-tolerated analogue, oxaliplatin, a valuable alternative agent in patients affected by NHL [8] , may minimize hematologic and extra-hematologic toxicity and so allow the delivery of gemcitabine and ifosfamide at adequate dose-intensity. Furthermore, strong synergy between gemcitabine and oxaliplatin has been documented by several clinical studies in lymphomas and other malignancies [9] . Finally, the inclusion of rituximab appears of value in sensitizing lymphoma cells to cytotoxic drugs and providing efficient in vivo purging [11] .
On the basis of predicted clinical activity, tolerability and synergy among drugs, the R-GIFOX regimen may offer an effective and less toxic alternative to cisplatin-based salvage regimens in lymphoma patients, including older adults. This paper presents preliminary data from a pilot study aimed at assessing the toxicity, activity and stem cell mobilizing capacity of R-GIFOX in patients with relapsed and refractory NHL of aggressive histology.
patients and methods patients
After obtaining written informed consent, 14 consecutive patients with relapsed or refractory aggressive NHL were accrued in this pilot study. Prior to salvage treatment, all patients underwent lymph node biopsy and had a histologically confirmed diagnosis of diffuse large cell lymphoma (DLBCL, n = 7), mantle cell lymphoma (MCL, n = 4), follicular cell lymphoma (FCL G3b, n = 3) according to WHO criteria [12] . All patients were required to have CD20
+ tumor cells as assessed by immunohistochemistry. Molecular genetic analysis of t(14;18)-BCL2/IgH and t(11;14)-CCND1/IgH translocations was performed by polymerase chain reaction (PCR) on lymph node tissues, bone marrow (BM) and peripheral blood (PB). Eligibility criteria included age >18 years, adequate organ function as defined by a creatinine clearance >60 ml/min, serum transaminases less than three times the normal value, bilirubin <2 mg/dl, left ventricular ejection fraction >0.45, Eastern Cooperative Oncology Group (ECOG) performance status £2, absolute neutrophil count ‡1500/ll, hemoglobin level ‡10 g/dl and platelets ‡100 000/ll. Patients were required to have negative human immunodeficiency virus tests and to be free of active infections. Primary progressive/refractory disease was defined as disease progression during the last chemotherapy line or only transient response (i.e. CR or PR lasting £3 months) after treatment. Progressive disease required the following: (1) ‡25% increase from nadir in the sum of the products of the greatest diameter of any previously identified abnormal node/lesion in partial responders or non-responders; and (2) the appearance of any new lesion within 3 months of the end of therapy. Relapsed disease was defined as disease progression after CR lasting ‡3 months.
study design and treatment
All patients were scheduled to receive three courses of bi-weekly R-GIFOX. Those eligible for ASCT and with a successful stem cell collection proceeded to HDT, while the others were given three additional courses of the salvage regimen. R-GIFOX (Table 1) and melphalan 140 mg/m 2 (day -2). PBSCs were reinfused at day 0 and a fixed single dose (6 mg) of pegylated-G-CSF administered at day +4. Treatment delays and dose reductions were planned in case of grade 3 and 4 toxicity, as assessed by the third revision of Common Toxicity Criteria, relabeled in September 2003 by the NCI (US) and extended by the NCIC (Canada) as CTCAE (Common Terminology Criteria for Adverse Events) Version 3.0. In patients £65 years, no dose reductions were planned in case of inadequate bone marrow recovery and treatment was delayed until the Annals of Oncology symposium article absolute neutrophil count was more than 1000/ll and the platelet count more than 50 000/ll. For patients aged >65 years, dose reductions were planned according to neutrophil or platelet nadir as follows: grade 3 toxicity, 25% dose reduction only for gemcitabine; grade 4, 25% dose reduction for gemcitabine, oxaliplatin and ifosfamide.
Since the overall rate of extra-hematologic toxicity for both gemcitabine and oxaliplatin, including grade 3-4 events, does not appear age-dependent, dose modulations relied only on toxicity grading. With grade 2 or less toxicity, no dose reduction was planned, with the exception of creatinine >1.5-3 · upper limit of normal. For all grade 3 events except alopecia, the total dose of drugs to be administered for the next courses was reduced by 25%. For any grade 4 extra-hematologic toxicity, interruption of treatment was to be considered.
staging procedures
Before salvage treatment, the extent of disease was assessed by chest X-ray, total body computed tomography (CT), fluorine-18 ( 18 F)-fluorodeoxyglucose positron emission tomography (FDG-PET) and bone marrow biopsy. Endoscopic assessment and magnetic resonance imaging were performed as appropriate, according to histology and disease sites.
Restaging was performed after three courses of R-GIFOX and all sites of initial disease were reassessed by FDG-PET and CT scan. Bone marrow biopsy for patients who had bone marrow involvement, and PCR analysis of BM and PB for those displaying a molecular marker, were performed at the end of the entire treatment program.
response assessment
Responses were evaluated by the integrated International Workshop Criteria (IWC) and FDG-PET [13] after the third course and after 1 month from the end of the entire program. Failure-free survival (FFS) was calculated from the first day of treatment, with failure defined as achieving less than PR, disease progression or death from any cause.
actual dose intensity 
patient characteristics
Fourteen patients, whose characteristics are summarized in Table 2 , were accrued in this pilot study. The median age was 63 years (range 37-78 years). Five patients (36%; four with DLBCL, one with MCL) were primary progressive/refractory to their last chemotherapy regimen and nine patients (64%; three with DLBCL, three with MCL and three with FCLG3b) had relapsed. Expression of CD20 by tumor cells was documented in all cases before starting R-GIFOX therapy. Patients had received a median of two previous chemotherapy programs (range 1-6), including CHOP and CHOP-like regimens. Eight patients (57%) had been given rituximab or ibritumomab tiutexan (Zevalin) as a part of their previous treatmens and four had received prior radiotherapy.
Ten patients (71%) were in stage IV at recurrence and two in stage III. Bulky disease and involvement of two or more extranodal sites were present in 36% and 43% of patients respectively, while BM involvement was documented in eight cases (57%). Seven patients (50%) were intermediate-high or high on the non-age adjusted International Prognostic Index (IPI) [14] .
treatment results
The median number of courses delivered was four (range one to six). Thirteen patients completed at least three courses of therapy and were evaluable for response. One 72-year-old-male with DLBCL at first relapse is not yet evaluable, due to an inadequate number of courses received.
As shown in Table 3 , the overall response rate (ORR) after three courses of R-GIFOX was 77% (95% CI 46.2% to 95%), with seven CRs and three PRs according to FDG-PET integrated IWC criteria. According to disease status, the ORR was 40% (one CR, one PR) for primary progressive/refractory patients and 89% (six CR, two PR) in relapsed patients. According to age, the ORR was 67% (four CR, two PR) for patients aged £65 years and 80% (three CR, one PR) for those over 65. At a median follow-up of 6 months (range 1-12), three patients with primary refractory disease (two DLBCL, one MCL) have died (one due to septic complications and two from progressive disease) and 10 patients are alive, seven in CR with a median response duration of 5+ months (range 2+ to 10+). At the time of writing, FFS is 79.6% (95% CI 56% to 99%). Interestingly, three of four patients with MCL obtained an objective response to R-GIFOX (two CR, one PR). The two CR patients also displayed a molecular response, as shown by disappearance of the t(11;14)-CCND1/IgH 'nested' PCR signal in BM and PB.
As shown in Figure 1 , delivering three bi-weekly courses of R-GIFOX allowed the achievement of a significant actual dose intensity for each of the three drugs in the combination. Median ADI values of 81%, 83.5% and 86.5% were calculated for gemcitabine, ifosfamide and oxaliplatin, respectively.
stem cell mobilizing capacity of R-GIFOX
Adequate stem cell mobilization was obtained in four of six eligible patients (Figure 2) , with a median peak number of CD34 + progenitors of 133/ll (range 55.3-263.4/ll), achieved at days +11 to +13. The median number of collected CD34 + cells was 2.56 · 10 6 /kg body weight (range 2.3-9.1 · 10 6 /kg). In all instances a single leukapheresis was performed. Interestingly, the two poor mobilizers were patients who had received previous radiotherapy to pelvic bone and dorsal vertebral tract. ASCT was performed in two patients with a successful engraftment in both cases. The median number of days to an absolute neutrophil count >0.5 · 10 9 /l was 9, and 12 to a platelet count >20 · 10 9 /l.
treatment-related toxicity
Toxicities related to the 49 courses of treatment delivered are detailed in Table 4 . One early septic death (clinically documented infection with G4 neutropenia) was recorded in a primary refractory DLBCL patient who had previously received R-CHOP chemotherapy and 99 Y-ibritumomab tiutexan. Hematologic toxicity was acceptable despite all patients having received prior chemotherapy (and, in four cases, radiotherapy). The most common grade 3 and grade 4 toxicity was thrombocytopenia, which was documented in 26% of courses, with four patients requiring only 1 unit of platelets unit. Grade 3/4 anemia was present in 20% of courses; grade 3/4 neutropenia occurred in 22%. Febrile neutropenia and infections complicated 8% and 6% of cycles, respectively.
As to non-hematologic toxicity, alopecia occurred in all patients. However, mucositis was not frequent and not severe, and nausea and constipation were mild and transient. No severe effects were reported on hepatic and renal function, although a transient increase in levels of transaminases was observed in seven courses. Cardiac toxicity, carefully assessed due to the advanced median age of the cohort of patients treated, was unremarkable. Only one patient had a precautionary cessation of treatment (after the fourth R-GIFOX course and after having achieved a CR) due to pre-existing cardiac comorbidity. One episode of encephalopathy was reported in a 74-year-old woman. This occurred within 12 h of the first dose of ifosfamide in the second course of treatment; but had fully reversed after 48 h. Peripheral sensory neuropathy was reported in 12 courses. In one patient, the oxaliplatin total dose was reduced by 25% at courses 5 and 6 due to the development of paresthesiae and sensory alterations interfering with swallowing and writing.
Overall, hematologic toxicity resulted in a 1-week delay in eight (16%) of the scheduled treatment cycles and delay plus dose reduction in four cycles (8%). No treatment delays occurred due to non-hematologic toxicity.
discussion
Results of this pilot study show that R-GIFOX salvage chemoimmunotherapy has very promising activity in recurrent or refractory aggressive B cell NHL. An ORR of 77% and a CR rate of 54% were obtained in a cohort of extensively pretreated patients, more than 50% of whom had received two or more prior lines of chemotherapy, which had included rituximab in 57% of cases. R-GIFOX was active and displayed a favorable profile of hematologic and extra-hematologic toxicity in both younger and older patients. Actual Dose Intensity Figure 1 . Agent-specific actual dose-intensity after three courses of R-GIFOX.
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The regimen was also able to mobilize adequate numbers of circulating CD34
+ cells, and hemopoietic engraftment occurred within the expected time in patients receiving ASCT. Furthermore, complete remissions, including molecular responses, were achieved in high risk histotypes such as MCL.
Based on these preliminary data, R-GIFOX appears to fulfill the requirements of an 'ideal' salvage regimen for aggressive Figure 2 . Hemopoietic progenitor-mobilizing capacity of R-GIFOX. Subcutaneous G-CSF was given at 10 lg/kg from day +6 of the third R-GIFOX course through leukapheresis. The number of CD34 + hemopoietic progenitors in PB was monitored daily by flow cytometry starting from day +9 to PBSC harvest or to day +13. Data are expressed as CD34 + cells ·10 9 /l. White blood cell counts (WBC ·10 9 /l) are also shown. Table shows number of cycles affected and percentage of total cycles in which the respective toxicity occurred. Other toxicities (grade 1 and 2, <10% of the total number of treatment cycles) included constipation, nausea, phlebitis.
-, not provided for the subcategory.
symposium article Annals of Oncology NHL. It utilizes drugs non-cross-resistant with anthracyclinebased CHOP and CHOP-like regimens, displays significant cytoreductive and stem cell mobilizing capacity and does not affect the engraftment potential of endogenous CD34 + precursors. Its good toxicity profile also ensures treatment delivery, for an adequate number of courses, to patients unfit for high-dose procedures because of age, myelosuppression, unsuccessful mobilization or pre-existing extra-hematologic toxicity/comorbidity. In terms of both activity and toxicity, R-GIFOX appears to compare favorably with other salvage regimens currently adopted for aggressive NHL (Table 5 ).
The design of R-GIFOX exploits the combination of gemcitabine, ifosfamide and oxaliplatin, all non-anthracycline agents displaying significant synergistic activity in vitro and in vivo and non-overlapping extra-hematologic toxicity [15] . In NHL, gemcitabine is an attractive substitute for cytarabine because of its greater single-agent activity, excellent safety profile and synergy with both platinum-coordination complexes and ifosfamide [16] . Response rates of at least 50% have been demonstrated in recurrent or progressive NHL when gemcitabine is combined with platinum derivatives.
Oxaliplatin also represents an attractive drug in lymphoma, due to its significant single-agent activity (ORR 27%-40%) and favorable toxicity profile [8] . It has shown promising synergy when combined with gemcitabine in patients with solid tumors and lymphoma. This is due to distinct mechanisms of action/ resistance and the absence of overlapping toxicity [18] . The cytotoxicity of the combination is sequence dependent in hemopoietic tumor cells, gemcitabine followed by oxaliplatin being more cytotoxic than the reverse sequence [9] . Even though the molecular mechanisms underlying such synergy are not perfectly understood, it has been suggested that, unlike cisplatin-DNA adducts, oxaliplatin-DNA adducts are unable to generate resistance [19] . Based on these data, the R-GIFOX design incorporates the sequential administration of gemcitabine and oxaliplatin at a 24-h interval (Table 1) .
Important issues in combining gemcitabine with platinum compounds are the dose intensity of the two drugs and their scheduling (i.e. bi-versus 3-weekly). Notably, a higher dose intensity of gemcitabine and the inclusion of rituximab seem to counter previous suggestions of a weak and transient control of recurrent lymphoma deriving from early reports of median progression-free survival (PFS) ranging from 3 to 5.3 months.
As previously reported, only two of 16 responders to dosedense gemcitabine (1500 mg/m 2 ) plus cisplatin (50 mg/m 2 ), given at days 1, 8, 22, 29, 42 and 49, relapsed. Disease-free survival was 87% at 3 years [20] . Similarly, 17 out of 22 patients responding to a bi-weekly combination of gemcitabine (1000 mg/m 2 ) and oxaliplatin (100 mg/m 2 ) plus rituximab, were in continuing CR at the time of evaluation [21] . In this study, gemcitabine was delivered at 100% of the intended dose in all patients [21] . In contrast, in a study of gemcitabine (1000 mg/m 2 , days 1-8), cisplatin (75 mg/m 2 , days 1-8) and dexamethasone (GDP) given every 3 weeks, dose reductions and dose delays occurred in 14% and 53% of cycles, respectively. This yielded a PFS of only 3.1 months in the subset of patients aged more than 65 years [17] .
In the present study, we have shown that G-CSF-supported bi-weekly administration of gemcitabine and oxaliplatin is feasible, safe and ensures an age-independent ADI of >80% for both drugs, even when combined with a third active cytotoxic agent, i.e. ifosfamide. The early onset and high quality of R-GIFOX-induced CRs is attested to by the strict FDG-PETintegrated IWC criteria adopted for response evaluation at the third course [13] .
The inclusion of ifosfamide, a bifunctional alkylator with strong cytoreductive and PBSC mobilizing activity, contributes significantly to the R-GIFOX combination. Ifosfamide, like other DNA-damaging agents, may be more effective when given in combination with gemcitabine since incorporation of the latter drug into damaged DNA appears to inhibit repair [15] . Results of a phase I trial combining low-modulatory doses of gemcitabine (90-200 mg/m 2 , days 2 and 4) with ifosfamide (2 g/m 2 for 4 days) and doxorubicin every 21 days support such a hypothesis since both considerable toxicity and antitumor effects were seen [15] .
Significant activity with acceptable toxicity has been reported with the F-GIV combination (pegfilgrastim, gemcitabine, ifosfamide and vinorelbine) in 36 patients with recurrent NHL [22] . A particularly valuable feature of ifosfamide is the ability, shared by its metabolites, to efficiently penetrate the blood-CSF (or CNS?) barrier after systemic administration. This appears to be of considerable therapeutic relevance since relapsing or progressing patients with aggressive NHL are at increased risk of CNS localization.
The addition of rituximab to GIFOX chemotherapy is supported by recent evidence that (as with cytarabine and cisplatin-containing combinations) activity of gemcitabine/ oxaliplatin can be further improved by anti-CD20 antibodies [21, 23] . Indeed, pretreatment with rituximab sensitizes drugresistant NHL cells to various cytotoxics and furthers clearance of malignant cells for both conventional therapy and [11] . Furthermore, its inclusion in salvage programs for recurrent CD20 + NHL almost doubles the CR rate achievable with the same combination of drugs alone (Table 5 ) [24] . Finally, the demonstrated activity of rituximab in re-treatment (i.e. in patients who have already received the antibody as a single agent or as a part of a previous treatment) allows its use in salvage programs for NHL patients who have been treated with R-CHOP-like induction combinations.
Our results suggest that the clinical activity, tolerability and synergy among drugs included in the R-GIFOX combination can offer even older patients, an intensive but less toxic alternative to cisplatin-based chemotherapy. In recent years, studies of salvage regimes for NHL have been increasingly targeted to younger patients eligible for ASCT, with a median age in the different cohorts ranging from 42 to 48 years [6, 24] . A combination treatment offering effective and less toxic cytoreduction and mobilization, together with a widening of age and comorbidity inclusion criteria, may represent a further advance in salvage strategies.
Given the demonstrated activity of gemcitabine, with and without oxaliplatin, in lymphoma histotypes including HD and intractable neoplasms such as MCL and T-cell NHL [16, 17, 25, 26] , the GIFOX program may constitute a valuable therapeutic platform for salvage regimens. R-GIFOX is currently being tested in a formal phase II single-arm study designed to assess its activity and safety as first-line salvage therapy for patients with relapsed/refractory aggressive B-cell NHL and HD.
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